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Abstract
The aims of this study were to investigate the role of poly(ADP-ribose) polymerase (PARP)-1 in dyslipidemia-associated
vascular dysfunction as well as autonomic nervous system dysregulation. Apolipoprotein (ApoE)
2/2 mice fed a high-fat diet
were used as a model of atherosclerosis. Vascular and autonomic functions were measured in conscious mice using
telemetry. The study revealed that PARP-1 plays an important role in dyslipidemia-associated vascular and autonomic
dysfunction. Inhibition of this enzyme by gene knockout partially restored baroreflex sensitivity in ApoE
2/2 mice without
affecting baseline heart-rate and arterial pressure, and also improved heart-rate responses following selective blockade of
the autonomic nervous system. The protective effect of PARP-1 gene deletion against dyslipidemia-induced endothelial
dysfunction was associated with preservation of eNOS activity. Dyslipidemia induced PARP-1 activation was accompanied
by oxidative tissue damage, as evidenced by increased expression of iNOS and subsequent protein nitration. PARP-1 gene
deletion reversed these effects, suggesting that PARP-1 may contribute to vascular and autonomic pathologies by
promoting oxidative tissue injury. Further, inhibition of this oxidative damage may account for protective effects of PARP-1
gene deletion on vascular and autonomic functions. This study demonstrates that PARP-1 participates in dyslipidemia-
mediated dysregulation of the autonomic nervous system and that PARP-1 gene deletion normalizes autonomic and
vascular dysfunctions. Maintenance of eNOS activity may be associated with the protective effect of PARP-1 gene deletion
against dyslipidemia-induced endothelial dysfunction.
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Introduction
Atherosclerosis, a major contributor to morbidity and mortality
in developed countries, is the underlying cause of a number of
cardiovascular diseases and is closely associated with dyslipidemia
[1,2]. Significant research has demonstrated that lipid-associated
disorders, such as atherosclerosis, are linked to alterations in
hemodynamic parameters, which may result in pathological
cardiovascular events [1,2,3]. Hypertension and dyslipidemia are
mechanistically linked and may act in synergy at the arterial wall
to enhance atherogenesis. The autonomic nervous system serves as
the main regulator of blood pressure and heart rate homeostasis, in
part, by modulation of the arterial baroreflex [4]. Indeed, reduced
spontaneous baroreflex sensitivity (SBRS) is associated with
impaired cardiac autonomic balance in hypertension, coronary
artery disease, and myocardial infarction [5,6]. In addition,
disruption in the balance between parasympathetic and sympa-
thetic tones can lead to cardiovascular dysfunction [6,7].
Endothelial dysfunction has been shown to be a reliable early
marker for atherosclerosis [8]. Nitric oxide (NO), a product of
endothelial NO synthase (eNOS), is released by the vascular
endothelium in response to various stimuli including acethylcho-
line (Ach), and plays an important role in endothelium-dependent
vasodilation. Molecular mechanisms responsible for endothelial
dysfunction may include decreased expression of eNOS protein,
alterations in the membrane signaling pathway leading to eNOS
enzymatic activation (e.g., signaling-induced eNOS phosphoryla-
tion), and decreased NO bioavailability through oxidants such as
superoxide (O2?2) [9,10]. Numerous studies have demonstrated
that hypercholesterolemia is associated with defects in NO-
dependent endothelial function in humans and in many
experimental models, including ApoE
2/2 mice [11,12]. Impaired
endothelium-dependent relaxation in response to ACh occurs in
the aorta [13] and the coronary arteries [14] of genetically-altered
hyperlipidemic mice.
Our laboratory recently demonstrated that poly-ADP-ribose
polymerase (PARP)-1 is activated within atherosclerotic plaques in
an animal model of atherosclerosis [15]. Indeed, decreasing
PARP-1 activity not only led to plaque stability, but actually
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[15,16,17]. These anti-atherogenic effects were associated with a
reduction in inflammatory factors such as TNF, ICAM, monocyte
chemoattractant protein (MCP-1). Additional effects include
cellular changes related to plaque dynamics such as an increase
in smooth muscle cell (SMC) content, decreased collagen
degradation, and increased TIMP-2 expression [15,17]. Support
for these observations is provided by a recent report by von
Lukowicz et et al [18].
Previous studies have demonstrated that PARP-1 activation
might be involved in vascular dysfunction associated with
circulatory shock, heart failure, ischemia reperfusion injury,
hypertension, and diabetes [19,20,21,22]. Inhibition of PARP-1
confers protection against many of these conditions [19,20,23,24].
However, the exact mechanism by which PARP-1 mediates
development of these diseases needs to be better clarified in order
for PARP-1 inhibition to be a potential target as a viable
therapeutic strategy for cardiovascular disorders.
Inthepresentstudy,weusedanintegrative approach toassessthe
role of PARP-1 in the pathogenesis of atherosclerosis-associated
vascular dysfunction and to investigate the effect of PARP-1 gene
knockout on autonomic function and endothelium dysfunction. We
also examined the relationship between occurrence of oxidative
stress in our experimental model and PARP-1 activation as a
potential mechanism for the manifestation of dyslipidemia-associ-
ated vascular and autonomic nervous system dysfunction.
Materials and Methods
Generation of PARP-1 and Double Knockout (DKO) Mice
on C57BL/6 Background
C57BL/6 wild-type, ApoE
2/2 (Jackson Laboratories, Bar
Harbor, ME, USA), and PARP-1
2/2 mice were housed and bred
in a pathogen-free animal care facility at LSUHSC (New Orleans,
LA) and allowed full access to standard mouse chow and water. All
experimental protocols were approved by the LSUHSC Animal
Care and Use Committee. C57BL/6 PARP-1
2/2 mice were
generated as described[25]. DKO mice were generated by
crossing PARP-1 heterozygous mice with ApoE
2/2 mice, as
described [15]. All animals were genotyped using polymerase
chain reaction (PCR). ApoE
2/2 mice fed a HF diet were used as a disease
model for the present studies because of the pathogenesis of autonomic and
vascular dysfunctions in these mice mimics that found in humans on a very
short time-scale[11].
Hemodynamic Parameters
4–6 weeks old male ApoE
2/2 and DKO mice (n=6) were fed regular
diet (RD) or high-fat diet (HF; Harlan Teklad, Madison, Wis) containing
21% fat by weight (0.2% cholesterol) for 16 weeks for histological studies.
The fat contents of the diet are manipulated to induce changes that are linked to
risk of cardiovascular disease in humans. Separate male ApoE
2/2 and
DKO mice (n=6) were fed under same diet regimen and
anesthetized and implanted with a radiotelemetry probe as
described[26]. Upon recovery from surgery (,1 wk), blood
pressure (BP) was recorded during 48 hours to determine baseline
hemodynamic parameters (i.e. systolic and diastolic BP, mean
arterial pressure (MAP) and heart rate (HR)). From baseline
recordings, spontaneous baroreceptor reflex sensitivity (SBRS) was
calculated using the sequence method as described[27]. Briefly,
from previous BP and HR recordings, all up (increase in BP and
decrease in HR) and down (decrease in BP and increase in HR)
baroreflex sequences were detected using Hemolab software
(http://www.harald.nxserve.net/HemoLab/HemoLab.php) and
the average SBRS was calculated.
Autonomic function was assessed using a pharmacological method
involving intraperitoneal injection (i.p.) of a b-blocker (propran-
olol, 8 mg/kg), a muscarinic receptor blocker (atropine, 1 mg/kg),
or a ganglionic blocker (hexamethonium, 20 mg/kg). All drugs
and doses were chosen for their ability to effectively block the
respective receptors. Additionally, vascular function was assessed
with acetylcholine (ACh; 2 mg/kg) and sodium nitroprusside
(1 mg/kg; Sigma Chemicals). Changes in HR were analyzed
30 min after administration of the antagonists as described[28].
Lipid profile, Histology, Immunohistochemistry, and
Immunoblot Analysis
For lipid profile, animals were fasted for 4 h and samples were
sent blindly to Cardiovascular Specialty Laboratories, Inc (Atlanta,
GA) for lipid assessment. Perfusion fixed aortas from various
genotypes were dissected and prepared for either Oil-Red-O
staining using standard protocol or paraffin embedding. Tissues
were sectioned (5 mm), subjected to hematoxylin and eosin (H&E)
or trichrome staining. Lesion areas were assessed as described
[15]. Hearts were paraffin embedded and sections were subjected
to immunohistochemistry (IHC) using standard protocols[15,16]
and processed for eNOS (Cell Signal, Danvers, MA), phosphor-
ylated eNOS (Sigma, St. Louis, MO), nitrotyrosine (Upstate, Lake
Placid, NY), or iNOS (BD Bioscience, San Jose, CA) detection.
Immunoblot analysis of protein extracts prepared from left
ventricle of the different experimental groups was conducted as
previously described [29]. Antibodies to eNOS or its phosphor-
ylated form were used to probe nitrocellulose membranes.
Real time PCR
RNA was extracted from left ventricle using the RNeasy Fibrous
Tissue Mini Kit (Qiagen, Valencia, CA). Primers used for eNOS
were as follows: forward, CAACGCTACCACGAGGACA; re-
verse: CTCCTGCAAAGAAAAGCTCTG from Sigma Genosys.
(St. Louis, MO). The b2actin primers were described[15].
Amplification, detection and data analysis were performed using
iCycler real-time PCR system (Bio-Rad Laboratories, Hercules,
CA, USA).
Statistical Analysis
Results are expressed as mean6SEM, from at least six mice per
group unless stated otherwise. Two way or one-way ANOVA for
repeated measures, followed by post hoc test, were performed
when appropriate using GraphPad Prism 5 (GraphPad Software,
San Diego, CA, USA). Immunohistochemistry data represent arbitrary
density units calculated using Pro-Image software and were summarized as a
percent of basal control. For the comparison between the same groups on
different diet regimen, one way ANOVA was employed to calculate statistical
differences. Differences were considered significant at P,0.05.
Results
PARP-1 Gene Deletion Reduces Atherosclerotic Lesion
Formation in High Fat Diet-Fed C57Bl/6 ApoE
2/2 Mice
In order to verify that PARP-1 gene deletion protects against
plaque formation in a murine model of atherosclerosis, aortas were
collected from ApoE
2/2 or DKO mice after a 16-week regimen
with regular (RD) or high-fat (HF) diet. As expected, en-face oil red
‘O’ staining of longitudinally cut aortas revealed that HF diet
induces numerous atherosclerotic plaques not only at the
brachiocephalic or curvature areas of the thoracic region, but
also all over the abdominal aorta (Figure 1A). PARP-1 gene
deletion markedly lowered the incidence of these lesions along the
PARP-1 & Vascular Dysfunction
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abdominal region (Figure 1A, B). Moreover, PARP-1 gene
deletion not only significantly decreased plaque size but also
plaque number (in parentheses) in ApoE
2/2 mice fed HF diet for
16 weeks. It is important to note that ApoE
2/2 mice fed RD for
16 weeks, developed few fatty streaks that were comparable to
those observed in their DKO counterparts (Figure 1A). These
results are consistent with previous observations from our
laboratory using pharmacological inhibitor or heterozygous mice
for PARP-1 on C57BL/6 genetic background[15] and findings
from von Lukowicz et al [18] using PARP-1
2/2 mice on a mixed
genetic background.
Lack of PARP-1 Improves Baroreflex Sensitivity without
Affecting Baseline Hemodynamic Parameters
One week prior to the completion of the diet regimens, the different
experimental groups were implanted with telemetry probes for BP
recording. Mice were then allowed to recover for one week before
measurements. As shown in Figure 2A, ApoE
2/2 mice on RD show a
significant reduction of SBRS consistent with our previous observa-
tions[30]. PARP-1 gene deletion restored baroreflex sensitivity in these
mice. This reversal was completely absent in HF-diet treated mice.
Baseline heart rate (HR) and mean arterial pressure (MAP) did not
significantly differ between groups and this was verified in the different
phases of the nycthemere (Figure 2B and C). Overall, these results
suggest that PARP-1 gene deletion may improve baroreflex sensitivity
at early stages of the disease and that HF diet reverses the beneficial
effects of PARP-1 deletion on baroreflex function.
PARP-1 Gene Deletion Improves HR Responses Following
Selective Blockade of the Autonomic Nervous System
Blockade of the parasympathetic drive by atropine (1 mg/kg)
resulted in similar tachycardic responses in both wild type (WT) and
ApoE
2/2 mice on RD, suggesting that vagal tone is not impaired in
this group (Figure 3A). However, this increase in HR in response to
atropine was significantly higher in DKO mice maintained on a
regular diet than in ApoE
2/2 mice on a similar diet regimen. HF
diet similarly reduced parasympathetic tone in ApoE
2/2 and DKO
mice, again showing that the beneficial effect of PARP-1 gene
deletion is reversed by HF diet. Blockade of sympathetic tone by
propranolol (8 mg/kg), a non-specific b-blocker, resulted in higher
bradycardic in WT mice compared to ApoE
2/2 mice on RD
suggesting that sympathetic tone is exacerbated in this mouse model
of atherosclerosis (Figure 3B). This impairment was reversed in
DKO mice fed RD. 16-week HF-diet regimen further exacerbated
sympathetic tone in ApoE
2/2 mice; DKO mice remain protected
against increased sympathetic tone. To exclude the possibility that
the beneficial effects of PARP-1 gene deletion on HR responses,
following atropine or propranolol administration, were due to
genetic alterations of cardiac function, a ganglionic blocker
(hexamethonium; 20 mg/kg i.p.), was administered and intrinsic
HR between the different groups was evaluated. As shown in
Figure 3B, when complete autonomic outflow was attenuated, the
intrinsic HR was comparable between the groups, showing that the
alterations observed in response to atropine or propranolol were not
due to changes in cardiac rhythm, but reflected significant
alterations of autonomic function.
PARP-1 Gene Deletion Prevents Dyslipidemia-Induced
Endothelial Dysfunction
In order to establish the role of PARP-1 in endothelial
dysfunction in conscious mice, the present study determined
whether PARP-1 gene deletion provides protection against
endothelium-dependent (acetylcholine; ACh) and independent
(sodium nitroprusside; SNP) vasodilators. As shown in Figure 3C,
both drugs lowered MAP in mice fed a RD. However, ACh-
induced MAP reduction was significantly improved in DKO mice
compared to ApoE
2/2 mice, suggesting that endothelium-
dependent vasodilation was preserved in these mice. After feeding
a HF diet regimen for 16 weeks, both mouse strains exhibited
similar impairments of endothelium-dependent vasodilation in
response to ACh. Again, while endothelium independent vasodi-
lation was similar in ApoE
2/2 and WT mice on RD, it was
significantly enhanced in DKO mice. Interestingly, although HF
diet further impaired the ability of the vessels to relax, endothelium
independent vasodilation was totally preserved in DKO mice. This
Figure 1. PARP-1 gene deletion promotes atherosclerotic
plaque reduction in an animal model of atherosclerosis. (A)
Aortas from the different experimental groups were formalin (PBS)-
perfused and atherosclerotic plaques were visualized by en face Oil-Red-
O staining. (B) Quantitation of plaque size and number (in parentheses)
were determined as described[15]; P value (,0.05) *compared to
ApoE
2/2 RD, {compared to ApoE
2/2 HF (16 weeks), and {compared to
DKO mice on RD.
doi:10.1371/journal.pone.0007430.g001
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endothelium-dependent dysfunction.
PARP-1 gene deletion ameliorates the atherogenic index
of high fat diet fed-ApoE
2/2 mice
Lipid profile data showed that DKO mice on RD exhibited
moderately higher levels of LDL and total cholesterol (Figure 4).
HDL-cholesterol in DKO mice on RD was markedly higher as
compared to ApoE
2/2 mice on similar diet regimen (Figure 4). As
expected, a 16 weeks HF diet regimen dramatically increased total
and LDL-cholesterol in ApoE
2/2 mice. However, such an
elevation in total and LDL-cholesterol was less pronounced in
DKO mice. Atherogenic index is increasingly regarded as a more
reasonable parameter of dyslipidemia rather than individual
cholesterols [31]. In our study, the atherogenic index was
significantly higher in ApoE
2/2 than in DKO mice on RD as
Figure 2. PARP-1 gene deletion improves spontaneous baroreflex sensitivity(SBRS). Data from telemetry recordings (average of 3
consecutive days) show restoration of SBRS by PARP-1 gene deletion in mouse model of atherosclerosis (A). Imroved SBRS response was not
associated with significant difference in average HR (B) or MAP (C) during day or night among these groups. This effect was however abolished after
feeding HF diet for 16 weeks (A). The data is expressed as mean 6 SEM from at least 6 mice in each group for 3 different set of experiments. P value
(,0.05) *compared to ApoE
2/2 RD and {compared to DKO mice on RD.
doi:10.1371/journal.pone.0007430.g002
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that dyslipidemia may be partly responsible for vascular and
autonomic dysfunctions and that protective effects of PARP-1
inhibition on these abnormalities may be mediated partly through
its effects on lipid profile (Figure 4).
Loss of PARP-1 Preserves eNOS Activity without Altering
Total eNOS Expression
In ApoE
2/2 mice, impaired responses to ACh could be due to
an alteration in either eNOS expression or eNOS activation
(eNOS phosphorylation). Immunohistochemical analysis of un-
Figure 3. Loss of PARP-1 preserves autonomic and endothelial functions. (A). In response to atropine (parasympathetic tone blockade;
1 mg/kg), tachycardia was higher in DKO mice on RD than ApoE
2/2, but high-fat diet abolished this effect. propranolol (sympathetic tone blockade;
8 mg/kg), induced higher bradycardic response in DKO than ApoE
2/2 and high-fat diet did not abolish this effect, Intrinsic HR determined following
hexamethonium treatment (ganglionic blockade; 20 mg/kg i.p.) was comparable among these groups (B). Increase in MAP after acetylcholine
(endothelium dependent vasodilator; 2 mg/kg) in DKO mice was higher than ApoE
2/2 mice (3C). In response to SNP, endothelium independent
vasodilation was similar in ApoE
2/2 and WT mice, it was improved in DKO mice. Interestingly, although HF diet further impaired the ability of the
vessels to relax, endothelium independent vasodilation was totally preserved in DKO mice. P value (,0.05) *compared to ApoE
2/2 RD, {compared to
ApoE
2/2 HF (16 weeks), and {compared to DKO mice on RD.
doi:10.1371/journal.pone.0007430.g003
PARP-1 & Vascular Dysfunction
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the different experimental groups revealed that total eNOS
expression was not altered when mice were maintained on a RD
or HF diet (Figure 5A, B). However, phospho-eNOS immunore-
activity was significantly greater in DKO than in ApoE
2/2 mice,
following either regular or HF diet (Figure 5C, D). These
observations were confirmed by immunoblot analysis of cardiac
extracts using the same antibodies (Figure 5E) and by RT PCR on
cDNA prepared from left ventricle of these mice (Figure S1).
PARP-1 Gene Deletion Reduces Protein Nitration in
Cardiac Tissue of HF-fed ApoE
2/2 Mice
Cardiac tissue from the HF diet-fed ApoE
2/2 mice exhibited a
high poly-ADP-ribose (PAR) immunoreactivity, indicating that
PARP-1 activity was elevated in these mice, while a significantly
lower PAR immunoreactivity was detected in ApoE
2/2 mice
receiving a RD (Figure 6A). No PAR immunoreactivity was
detected in cardiac tissue prepared from HF or RD-fed DKO
mice. PARP-1 activation was mirrored by an increase in protein
nitration as assessed by nitro-tyrosine immunoreactivity
(Figures 6B&C), establishing a potential association between
PARP-1 activation and oxidative stress. Protein nitration was
decreased in tissue of HF diet-fed DKO mice (Figures 6D&E).
Discussion
The results of the present investigation demonstrate that PARP-
1 participates in dyslipidemia-mediated vascular dysfunction and
dysregulation of autonomic function and that PARP-1 gene
deletion is protective against these defects. Previously, our
laboratory demonstrated that PARP-1 inhibition affects athero-
sclerotic plaque dynamics and these alterations are highly
desirable for the control of plaque progression and promotion of
stability [15,16]. Dynamics of atherogenesis are confined to
atherosclerotic plaques but are integral participants of overall
vascular dysfunction including hypertension, myocardial infarction
and heart failure. The present study is a direct continuation of our
ongoing investigation of the role of PARP-1 in atherosclerosis and
associated pathologies.
Figure 4. PARP-1 inhibition decreases atherogenic index in ApoE
2/2 mice on HF diet for 16 weeks. Lipid profile data of 4 h starved mice
shows that PARP-1 inhibition significantly increased HDL-cholesterol and total cholesterol in ApoE
2/2 mice on regular diet (4A and 4C). After feeding
HF diet for 16 weeks, total and LDL-cholesterol increased dramatically in ApoE
2/2 mice. The increase in total and LDL cholesterol in DKO mice was
significantly lower than ApoE
2/2 mice on similar diet regimen (4A and 4B). Though HF diet significantly decreased HDL-cholesterol in DKO mice,
atherogenic index still remained significantly higher in ApoE
2/2 mice than DKO mice (Figure 2D). The data is expressed as mean6SEM from at least 6
mice in each group for 3 different set of experiments. P value (,0.05) *compared to age matched ApoE
2/2 RD, {compared to ApoE
2/2 HF (16
weeks), and {compared to age matched ApoE-PARP-1
d2/2 mice on a regular diet.
doi:10.1371/journal.pone.0007430.g004
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andC show IHCdata with antibodies toeNOS or phospho-eNOS respectively of heart from ApoE
2/2 andDKOmice ona regular or high-fatfor16 weeks.
Figures 5 B and D represent quantitation of immunoreactivity, performed using Image-Pro Plus software and expressed as immunoreactivity/mm
2.( E )
WesternBlotofleft ventricles isolatedfromtheseexperimentalgroups (n=6)werecollectedandsubjectedtoproteinextractionandwestern blottedfo r
phopho-eNOS, or total eNOS. Scale bar: 50 mm. P value (,0.05) *compared to ApoE
2/2 RD, {compared to ApoE
2/2 HF (16 weeks), and {compared to
DKO mice on RD.
doi:10.1371/journal.pone.0007430.g005
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nitrotyrosine and iNOS in heart. Heart isolated from these experimental groups were collected and subjected to immunohistochemistry with
antibodies to PAR (A), nitrotyrosine (B) and iNOS (C). Figures 6C and E represent quantitation of immunoreactivity was conducted using Image-Pro
Plus software and expressed as immunoreactivity/mm
2. Scale bar: 50 mm. P value (,0.05) *compared to ApoE
2/2 RD, {compared to ApoE
2/2 HF (16
weeks), and {compared to DKO mice on RD.
doi:10.1371/journal.pone.0007430.g006
PARP-1 & Vascular Dysfunction
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primary outcomes of dyslipidemia. Thus, devising strategies that
can diminish or completely block the manifestation of these
outcomes is of great clinical importance. In this study, we
demonstrate that PARP-1 plays an important role in both
dyslipidemia-associated vascular and autonomic dysfunction.
Inhibition of this enzyme by gene knockout partially improved
baroreflex sensitivity, without affecting baseline hemodynamic
parameters, and improved autonomic function. It also prevented
dyslipidemia-induced endothelial dysfunction, possibly through
maintenance of eNOS activity. Moreover, modulation of oxidative
tissue damage may underlie the observed protective effects of
PARP-1 gene knockout.
The arterial baroreceptor reflex is a classic negative feedback
mechanism that is critical for maintaining BP around a setpoint by
sensing its fluctuations and correcting accordingly [32,33]. In
recent years, a great deal of evidence has accumulated that
supports the ability of dyslipidemia and its associated pathologies
to impair SBRS in humans [32,33]. In fact, Nasr et al. recently
showed that bilateral carotid atherosclerosis in human patients is
associated with an impairment of SBRS and a shift of the
sympathovagal balance toward a decrease in parasympathetic-
associated HR variability[33]. Many of these changes are clearly
associated with elevated oxidative stress. Our laboratory previ-
ously reported that oxidative stress contributes to autonomic
dysregulation in hypertensive and hypercholesterolemic mice[30].
The negative effect of dyslipidemia on SBRS observed is consistent
with our previous studies done in ApoE
2/2 mice, with the effects
of dyslipidemia observed in humans as well as in LDL-receptor
knockout mice, as very recently reported by Campos et al[34]. It is
noteworthy that changes in SBRS regulation may be mainly
mediated by parasympathetic tone, an idea also set forth by Tank
et al[35]. Furthermore, the parasympathetic tone seems more
sensitive to dyslipidemia than sympathetic tone. A rather
important and interesting finding in this study is that PARP-1
gene deletion preserved SBRS in regular diet-fed mice, but this
protective effect was completely abolished in HF diet-fed animals.
The mechanism through which a HF diet overwhelms the
protective effect of PARP-1 gene deletion is unknown.
PARP-1 gene deletion preserved parasympathetic tone in RD-
fed mice, but failed to do so in mice fed a HF diet. Conversely,
PARP-1 deficiency significantly prevented exacerbated sympa-
thetic tone not only in regular diet-fed ApoE
2/2 mice, but also in
HF diet-fed animals. The reason(s) for the ability of DKO mice to
maintain these responses during a regular diet regimen is unclear,
and the reason(s) for their ability to maintain parasympathetic tone
responses during a high-fat diet is even more puzzling. These
discrepancies are not unprecedented, as Rose et al[36] reported
that PI3K
2/2 mice displayed similar responses, which were
attributed to negative regulation of cAMP by PI3K in the
ventricular myocardium. Whether PARP-1 deficiency may affect
the autonomic nervous system through a mechanism involving
PI3K activity and cAMP is unknown, although poly(ADP-
ribosyl)ation of the PI3K family member, DNA-dependent protein
kinase, has been shown to enhance its kinase activity [37].
However, as eluded to earlier, oxidative stress has become
increasingly regarded as an important participant in vascular
impairments. Therefore, PARP-1 gene deletion may preserve
cardiovascular function by modulating factors that instate
oxidative stress. Inhibition of iNOS overexpression and subse-
quent nitrergic damage may be one such example.
Our data suggests that though PARP-1 gene deletion moder-
ately increased total cholesterol levels on regular diet regimen, but
HF diet induced higher total and LDL- cholesterol in ApoE
2/2
mice than DKO mice. Moreover, PARP-1 gene deletion
significantly increased HDL-cholesterol, an effect which was
abolished by HF diet. Interestingly, von Lukowicz et al[18]
reported significantly higher levels of total and LDL- cholesterol in
DKO mice as compared to ApoE
2/2 mice which is in contrast to
our data. However, in their study, they used 1.25% total
cholesterol in their diet which is 6 times higher than HF diet
used in our studies (0.2% cholesterol). Further mice used in our
study are from homogenous background (C57BL/6J). Atherogenic
index, which has been suggested as better index of dyslipidemia
and important tool to analyze the results considering the
complexity of lipoproteins[31] was significantly decreased by
PARP-1 gene deletion in both RD and HF regimen. Interestingly
PARP-1 gene deletion increased HDL by double in regular diet
group, an effect which was abolished by HF diet. Though
mechanism of increased HDL levels by PARP-1 gene deletion is
unknown, HDL- cholesterol has independently been reported to
correlate with autonomic and vascular dysfunctions[38,39].
ApoE
2/2 mice can develop atherosclerotic lesions while on a regular diet
but require a lengthy duration [40]. In fact, complicated and multilayered
plaques lesions such as those observed in humans require near or more than a
year to take place. However, it remains rather interesting and important to
assess the effect of long term regular diet on the deterioration of autonomic and
vascular functions and protective effects by PARP inhibition.
Many studies, including those from our laboratory, have shown
that PARP-1 inhibition greatly reduces expression of
iNOS[41,42]. Several groups, including ours, have demonstrated
the responsiveness of PARP-1 to oxidative stress and its
participation in oxidative stress-associated endothelial and cardiac
dysfunctions [15,16,19]. In fact, our laboratory recently demon-
strated that a more complex relationship between PARP-1 and
iNOS exists, as these two proteins are reciprocally regulated
during airway inflammation with NF-kB activation serving as
major component of this relationship[43]. Notably, NF-kB
regulates the expression of iNOS during inflammation[42]. NF-
kB has also been suggested to regulate NADPH oxidase subunit
p22 (phox) in human aortic smooth muscle cells[44]. Therefore,
PARP-1 deficiency may exert an antioxidant effect and maintain
autonomic nervous system through a direct effect on NAD(P)H
oxidase complex function. Obviously, this hypothesis needs to be
confirmed through additional experimentation.
Endothelial NOS (eNOS) activity is thought to have an
important influence on the activity of the sympathetic tone[45].
Pathological processes that reduce vascular NO may do so
through down regulation of eNOS expression or inhibition of
eNOS activity. They may also reduce vascular NO by decreasing
NO bioavailability, an effect attributable to NO inactivation by
radicals such as O2
2, which generates the noxious byproduct,
peroxynitrite (ONOO
2)[46]. Thus, increased oxidative stress in
the vascular wall is a key mechanism underlying endothelial
dysfunction[46]. The increased levels of protein nitration in
cardiac tissues of HF diet-fed animals is evidence for increased
levels of ONOO2, which would be suggestive of a decrease in NO
bioavailability and may explain the observed endothelial dysfunc-
tion in these animals[47]. Therefore, it is tempting to speculate
that the ability of PARP-1 deficiency to prevent such extensive
oxidative stress and to maintain eNOS activity underlies
protection against endothelial dysfunction and dysregulated
autonomic nervous system.
Numerous studies of PARP-1 involvement in oxidative stress-
associated endothelial dysfunction, primarily using cell culture and
ex vivo systems, have demonstrated that pharmacological inhibition
of PARP-1 confers protection against such dysfunction (for
review[19,23]).
PARP-1 & Vascular Dysfunction
PLoS ONE | www.plosone.org 9 October 2009 | Volume 4 | Issue 10 | e7430In conclusion, using conscious animals we have demonstrated
that PARP-1 participates in dyslipidemia-mediated vascular
dysfunction and dysregulation of autonomic function and that
PARP-1 gene deletion is protective against these defects. Future
studies may better clarify the mechanism by which PARP-1
participates in autonomic nervous system function.
Supporting Information
Figure S1 RT PCR shows similar eNOS expression in heart or
aorta of ApoE2/2 mice and DKO mice suggesting that PARP-1
inhibition is affecting activation (phosphor-eNOS) rather than
amount of eNOS. cDNA generated from the heart or aorta extract
was subjected to PCR using the primers described in the Materials
and Methods generating a single PCR product.
Found at: doi:10.1371/journal.pone.0007430.s001 (0.06 MB TIF)
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